One plausible explanation for the synergistic anti-tumor effects is that rapamycin and crizotinib share common AKT-mTOR axis and its down-stream target molecules, NANOG and OCT4, as these are considered to be essential for tumor maintenance in many malignancies [28, 44, 45]. This evidence concerns the gene NANOG and neoplasm.